Hilary Kramer

Hilary Kramer

Hilary Kramer is one of Wall Street’s most successful equity analysts and investment managers, with a reputation as a leading expert on today’s market movements, stock trends and economic outlook.

She received her MBA from the Wharton School at the University of Pennsylvania and her BA from Wellesley College with honors. Hilary Kramer got her start on Wall Street more than two decades ago at Lehman Brothers and Morgan Stanley where she was an analyst in the investment banking group covering natural resources, diversified industrials and energy companies. She was also the chief investment officer of a family office — overseeing a $5.2 billion global private equity and publicly-traded equity fund, and co-vice chairman of the $500 million Ibero-American Partners Fund (1997 to 2003).

In 2004, Hilary’s A&G Capital formed a specialized research arm and investment fund. The GreenTech 21st Century Master Fund focused on companies engaged in alternative energy, clean technologies, environmental infrastructure and services, agricultural and natural resources.

Today, Hilary Kramer is an in-demand commentator whose work often appears in investing publications such as the Wall Street Journal, New York Post, Bloomberg, Business Insider and Reuters and is a regular on CNBC, CNN and the Fox News Channel, providing stock market insight and economic observations.

Hilary Kramer is also the editor of several financial advisory services designed to help individual investors profit from her stock picking talents: Value Authority, GameChangers, Breakout Stocks, High Octane Trader, Absolute Capital Return, Inner Circle and Inner Circle Pro.

Recent Articles

Trade of the Day: PayPal (PYPL)

I like that PYPL has an upcoming catalyst when it joins the Nasdaq 100 this week.

Whole Foods: Why WFM Stock Is Still a Sell

Misses combined with drastically slowing growth push WFM stock lower - and it could drop further still.

Why You Should Believe (and Buy) the Current Rebound in Biotech Stocks

Price gouging may have summoned Hillary Clinton's wrath, but the selloff in biotech stocks was built on fearmongering, while the rebound is being built on actual substance.

AMZN: Why Amazon Stock Is Still a Buy

AMZN is a retail powerhouse, technological leader and great investment. Strong fundamentals and innovation should push Amazon stock higher.

Cash In on Citigroup Stock (C)

Citigroup stock has traded sideways for a year, but its prospects are finally looking up.

Taking a Bite Out of GrubHub (GRUB)

GrubHub is the latest name to fall victim to the swinging axe of earnings season, as shares of GRUB were pulled down by spooked investors.

Two Pharma Giants Become One (WBA, RAD)

When WBA purchases RAD, it'll push toward 41% market share at a bargain price -- and in a great retail sector.

BABA Stock’s Earnings Beat Sparks Near-Term Potential

If you’re looking for some exposure to Shanghai’s recovery, BABA stock holds great potential as a short-term trading opportunity.

3 Reasons 3M Stock Still Isn’t a Buy

3M stock continues to struggle, even after its recent earnings beat. MMM has many obstacles to overcome to retain investor confidence.

YUM Stock: Recent Split Is Simply a Sidetrack

Splitting into Yum Brands and Yum China won't save YUM stock. The move is simply one of desperation and a lack of better solutions.